Comparing Budesonide/Formoterol Inhalers for Asthma Treatment
Author Information
Author(s): Morice A H, Peterson S, Beckman O, Osmanliev D
Primary Institution: University of Hull
Hypothesis
Is the new HFA pressurised metered-dose inhaler (pMDI) formulation of budesonide/formoterol more effective than existing inhalers?
Conclusion
Both the HFA pMDI and DPI formulations of budesonide/formoterol are effective and well-tolerated treatments for asthma.
Supporting Evidence
- Budesonide/formoterol pMDI showed a significant increase in morning PEF compared to budesonide pMDI.
- Both budesonide/formoterol therapies improved asthma symptoms more than budesonide pMDI.
- Patients reported similar health-related quality of life improvements with both budesonide/formoterol devices.
Takeaway
This study looked at different inhalers for asthma and found that a new type works just as well as the older ones.
Methodology
A 12-week, multinational, randomised, double-blind, double-dummy study involving patients aged ≥ 12 years with asthma.
Limitations
The study did not include a clinical trial registration identifier as it began enrolment before the required date.
Participant Demographics
Patients aged 12 years and older, with a mix of genders and a range of asthma severity.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: −10.4 to 4.9
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website